美国 · 股市与财经 · Morningstar
Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting
Four-year REMAIN data from the RESTORE Phase 2b/3 trial of MCO-010 in retinitis pigmentosa and a scientific poster on dry AMD to be presented at the AAO 2026 Annual Meeting,…
在 Morningstar 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.morningstar.com)
